A Randomized, Multicenter, Double Blind, Phase II Study of Neoadjuvant Nivolumab or Placebo Plus Chemotherapy Followed by Surgery and Adjuvant Treatment in Subjects With Resectable Esophageal Squamous Cell Carcinoma
Latest Information Update: 07 Jun 2024
At a glance
- Drugs Cisplatin (Primary) ; Fluorouracil (Primary) ; Nivolumab (Primary) ; Paclitaxel (Primary)
- Indications Oesophageal cancer; Squamous cell cancer
- Focus Therapeutic Use
Most Recent Events
- 12 Jun 2022 Status changed from not yet recruiting to recruiting.
- 03 Feb 2022 New trial record